The connection between sleep and Alzheimer’s disease has been a topic of interest among researchers. A study published in 2023 explored the impact of using sleeping pills, specifically suvorexant, on the build-up of toxic proteins in the brain. The study conducted by researchers from Washington University in St. Louis found that taking suvorexant for two nights at a sleep clinic led to a slight reduction in two proteins, amyloid-beta and tau, which are associated with Alzheimer’s disease.
Sleep disturbances have been identified as an early warning sign of Alzheimer’s disease, preceding symptoms such as memory loss and cognitive decline. As the disease progresses, abnormal levels of amyloid-beta can form clumps called plaques, which inhibit brain cell function. Promoting healthy sleep patterns may help in flushing out these proteins and waste products from the brain, potentially delaying the onset of Alzheimer’s disease.
While the study showed promising results regarding the role of sleeping pills in reducing protein build-up in the brain, it is important to approach these findings with caution. Neurologist Brendan Lucey, who led the research, cautioned against interpreting the results as a reason to start taking suvorexant every night. Prolonged use of sleeping pills can lead to dependence and may disrupt normal sleep cycles, which could exacerbate cognitive decline in the long term.
The study involved 38 middle-aged participants with no cognitive impairments or sleep issues. After receiving doses of suvorexant or a placebo, researchers monitored changes in protein levels in the cerebrospinal fluid over a 36-hour period. Results showed that amyloid-beta concentrations decreased by 10 to 20 percent with suvorexant, while hyperphosphorylated tau levels also saw a temporary decline.
Although the study highlighted the potential benefits of improving sleep quality with the use of sleeping pills, further research is needed to determine the long-term effects. Lucey remains hopeful that future studies involving older adults and extended use of sleeping pills could yield more conclusive results. Understanding the underlying causes of Alzheimer’s disease and how sleep affects protein levels in the brain is crucial in developing effective prevention strategies.
While the link between sleep and Alzheimer’s disease shows promise, it is essential to approach the findings with a critical mindset. Using sleeping pills as a preventative treatment for Alzheimer’s disease may not be the most effective approach, considering the complexity of the disease’s pathology. Improving sleep hygiene and addressing sleep-related issues like sleep apnea remain practical ways to support overall brain health. As research in this field continues to evolve, there may be opportunities to develop targeted interventions that leverage the relationship between sleep and cognitive function.